Geron (NASDAQ:GERN) Stock Rating Lowered by Robert W. Baird

Geron (NASDAQ:GERN) was downgraded by equities research analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a report issued on Tuesday, Briefing.com reports. They currently have a $4.50 price objective on the biopharmaceutical company’s stock. Robert W. Baird’s price target would indicate a potential upside of 8.70% from the stock’s previous close.

GERN has been the topic of several other reports. The Goldman Sachs Group raised their target price on Geron from $4.00 to $5.00 and gave the company a “buy” rating in a report on Friday, March 15th. TD Cowen assumed coverage on Geron in a research note on Monday. They issued a “buy” rating and a $10.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of Geron in a research note on Thursday, April 11th. Finally, Wedbush reiterated an “outperform” rating and issued a $6.00 price objective on shares of Geron in a research note on Wednesday, April 10th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.10.

Geron Price Performance

Shares of NASDAQ:GERN opened at $4.14 on Tuesday. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.14. Geron has a 1 year low of $1.64 and a 1 year high of $4.30. The business has a fifty day simple moving average of $2.89 and a 200 day simple moving average of $2.31. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -12.55 and a beta of 0.61.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Geron had a negative return on equity of 63.33% and a negative net margin of 77,691.14%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. During the same period last year, the company earned ($0.10) earnings per share. The business’s revenue was down 77.7% compared to the same quarter last year. As a group, sell-side analysts predict that Geron will post -0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Geron

Institutional investors have recently made changes to their positions in the business. Pathstone Family Office LLC acquired a new stake in Geron during the third quarter worth about $26,000. China Universal Asset Management Co. Ltd. grew its position in Geron by 101.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 6,757 shares in the last quarter. Federated Hermes Inc. acquired a new stake in Geron during the third quarter worth about $29,000. SG Americas Securities LLC acquired a new stake in Geron during the third quarter worth about $40,000. Finally, Twin Peaks Wealth Advisors LLC acquired a new stake in Geron during the fourth quarter worth about $58,000. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.